The share price of Aurobindo Pharma had dropped 30 per cent on-year basis till yesterday and after today's surge in share price the fall has been reduced to 18 per cent from a year-ago period. Aurobindo Pharma has registered a net profit of Rs 705.3 crore in Q3FY20 as against Rs 712.2 crore in the corresponding previous period. Revenue from operations stood at Rs 5,895 crore with a growth of 11.9 per cent over the corresponding previous period, buoyed by formulation revenues which had a growth of 17.4 per cent to Rs 5,104.9 crore and accounted for 86.6 per cent of total revenues. While the US formulations revenues registered Rs 2,969.4 crore as against Rs 2,433.2 crore in Q3FY19, a growth of 22.0 per cent from a year ago. In November, when the company received the observations, it had said that none of the observations were related to data integrity. Unit IV significantly contributes to the revenue and operating profit of the firm.